Cancer drugs funding

Spend on high-cost medicines contributing to NHS budget overspend, MPs warn

Excessive spending on specialised services fuelled by use of high-cost medicines and medical equipment is threatening the ability of the NHS to fund wider NHS services, MPs on the Public Accounts Committee have warned.…

More data needed for ibrutinib before NICE considers its place on cancer drugs fund

For the first time, the National Institute for Health and Care Excellence (NICE) has asked a pharmaceutical company to provide evidence so that its anticancer drug can be considered for inclusion in the cancer drugs fund.…

NICE to take control of England’s Cancer Drugs Fund

NHS England is pushing ahead with its proposed changes for England’s Cancer Drugs Fund, which will be run by the National Institute for Health and Care Excellence from 1 July 2016 in an attempt to plug a growing hole in the fund’s budget.…

NHS England has not managed Cancer Drug Fund properly, MPs say

The Cancer Drugs Fund has not been managed properly by NHS England and the Department of Health, a committee of MPs says.…

NICE to drop ‘only-in-research’ category for cancer drugs

The National Institute for Health and Care Excellence (NICE) has revealed that, where there is not enough evidence to support routine use of a cancer drug, it will no longer recommend the use of the drug as part of a clinical trial.…

Review of 2015: ten developments that are changing pharmacy

The pharmacy landscape continues to shift amid a backdrop of austere UK public spending and the rising spectre of centralised dispensing in the community. The Pharmaceutical Journal presents ten developments that affected pharmacists in 2015.…

Advanced breast cancer drug Kadcyla rejected by NICE

A drug to treat a type of advanced breast cancer has been rejected for use on the NHS because it is too expensive.…

UK pays less than European neighbours for cancer drugs

The price of originator cancer drugs varies widely between high-income countries and the UK pays one of the lowest prices in Europe.…

Proposals for revamped cancer drugs fund offer faster access to most promising drugs

New proposals have been drawn up for a revamped cancer drugs fund after the present model was branded unsustainable.…

Everolimus is available to patients in Wales after deal agreed with Novartis

Everolimus has been made available to treat patients in Wales with certain types of renal, pancreatic or breast cancers, or non-cancerous brain or kidney tumours associated with tuberous sclerosis complex.…